Diligence memo · auto-generated · as of July 2, 2026

Laxmi Therapeutic Devices, Inc.

Laxmi Therapeutic Devices, Inc. looks over-valued against its niche peers and is quiet on financing cadence.

WatchModeled above niche peers — entry today likely prices in growth not yet evidenced in the filings.

Businessfiled

Laxmi Therapeutic Devices, Inc. operates in Biotech / Pharma, based in GOLETA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Laxmi Therapeutic Devices, Inc. has raised $58M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $15M on 2024-07-31.

Most recent recorded round closed around 2024-07-31.

Valuation (modeled)modeled

Provath models Laxmi Therapeutic Devices, Inc. at approximately $75M (range $17M–$160M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.93× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 23 mo ago; this sector typically re-raises about every 15 months.

Slightly overdue versus sector cadence.

The last round was 3.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 90% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 65% of those peers.

Closest niche peers: Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc., NJ BIO, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.